Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.92 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.92 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.92 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.92 |
| ▸ | FAAH | O00519 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | CNR2 | P34972 | 1/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.74 |
| ▸ | SELP | P16109 | 1/20 | 0.70 |
| ▸ | DGKA | P23743 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10452609 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL10492136 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL19564925 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL6524506 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL2477265 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3182554 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL17512151 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL16431079 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL3181278 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL8388194 | 1.00 | PRKCA (0.92) | PRKCAPRKCEPRKCQPRKCDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599572-B2 | Solid lipid nanoparticles of curcumin | Punjab University Chandigarh (IN) | 2026-04-14 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-112986425-B | PM 2.5 Detection marker for influence on lipid metabolism and application | 首都医科大学 | 2023-07-04 | — | — | CN | claimed |
| US-20230064246-A1 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-03-02 | — | — | US | claimed |
| EP-4055192-A1 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| CN-114544924-A | Application of glyceride in disease prediction | 中国科学院上海营养与健康研究所 | 2022-05-27 | — | — | CN | claimed |
| US-20220151945-A1 | SOLID LIPID NANOPARTICLES OF CURCUMIN | REGISTRAR, PANJAB UNIVERSITY CHANDIGARH (IN) | 2022-05-19 | — | — | US | claimed |
| US-20200368313-A1 | DRUG DELIVERY SYSTEMS FOR TREATMENT OF INFECTIONS | WAYNE STATE UNIVERSITY (US) | 2020-11-26 | — | — | US | claimed |
| EP-3731846-A1 | DRUG DELIVERY SYSTEMS FOR TREATMENT OF INFECTIONS | Wayne State University (US) | 2020-11-04 | — | — | EP | claimed |
| US-20190192479-A1 | IMMUNOMODULATOR | NOSTER INC. (JP) | 2019-06-27 | — | — | US | claimed |
| EP-3501519-A1 | IMMUNOMODULATOR | National University Corporation Nara Institute of Science and Technology (JP) | 2019-06-26 | — | — | EP | claimed |
| US-20190125721-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | NEUROTROPE BIOSCIENCE INC (US) | 2019-05-02 | — | — | US | claimed |
| EP-3452482-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | Neurotrope Bioscience, Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| US-20190054070-A1 | Methods and Compositions for Regenerative Synaptogenesis | NEUROTROPE BIOSCIENCE, INC. | 2019-02-21 | — | — | US | claimed |
| WO-2018187647-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISEASES, DISORDERS, OR CONDITIONS | NEUROTROPE BIOSCIENCE, INC. (US) | 2018-10-11 | — | — | WO | claimed |
| US-9907758-B2 | Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins | PANJAB UNIVERSITY DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2018-03-06 | — | — | US | claimed |
| WO-2017192906-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | NEUROTROPE BIOSCIENCE, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-20140348938-A1 | PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2014-11-27 | — | — | US | claimed |
| US-20140212949-A1 | METHOD FOR PREPARING MICROVESICULAR ADAM15 | INDUSTRY ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) | 2014-07-31 | — | — | US | claimed |
| WO-2013105026-A1 | A PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2013-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151945-A1 | SOLID LIPID NANOPARTICLES OF CURCUMIN | PLIN1, LIPC, NPC1L1 | PRKCA 1368/4885PRKCE 1601/4885PRKCQ 2442/4885 |
| US-20190125721-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | PRKAR2B, PRKAR2A, PRKCH | PRKCA 11/4885PRKCE 17/4885PRKCQ 21/4885 |
| US-20140348938-A1 | PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | VDR, RARA, STRA6 | PRKCA 1047/4885PRKCE 1233/4885PRKCQ 2405/4885 |
| US-20190054070-A1 | Methods and Compositions for Regenerative Synaptogenesis | PRMT7, DCX, EZH2 | PRKCA 38/4885PRKCE 91/4885PRKCQ 24/4885 |
| US-12599572-B2 | Solid lipid nanoparticles of curcumin | CPT1A, CPT2, SCD | PRKCA 742/4885PRKCE 552/4885PRKCQ 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.